nach oben

Head and Neck Pathology

Erschienen in:

06.11.2023 | Review

Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations

verfasst von: Ruben Bill, William C. Faquin, Sara I. Pai

Erschienen in: Head and Neck Pathology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Immune checkpoint inhibitors have improved the outcome of patients diagnosed with inoperable recurrent or metastatic head and neck squamous cell carcinoma. However, as only a subset of head and neck cancer patients benefit from this treatment, biomarkers predicting treatment response help guide physicians in their clinical decision-making. PD-L1 expression assessed by immunohistochemistry is the single most clinically relevant biomarker predicting response to PD-1-blocking antibodies. Here, we discuss in which clinical context assessment of PD-L1 expression is instrumental for the choice of therapy, how pathologists score it, and how it affects the approval of anti-PD-1 antibodies. Furthermore, we discuss the heterogeneity of PD-L1 expression and review technical aspects of determining this prominent biomarker—knowledge that might influence clinical decision-making.

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6:92. https://doi.org/10.1038/s41572-020-00224-3CrossRefPubMedPubMedCentral

Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7CrossRefPubMed

Cohen EEW, Soulières D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393:156–167. https://doi.org/10.1016/S0140-6736(18)31999-8CrossRefPubMed

Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867. https://doi.org/10.1056/nejmoa1602252CrossRefPubMedPubMedCentral

Keytruda PD-LTS, MERCK (2023) https://www.keytrudahcp.com/biomarker-testing/pd-l1/ Accessed 31 Aug 2023

Moehler MH, Kato K, Arkenau H-T et al (2023) Rationale 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). J Clin Oncol JCO 41:286CrossRef

Nenclares P, Rullan A, Tam K, Dunn LA, St John M, Harrington KJ (2022) Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations. Am Soc Clin Oncol Educ Book 42:1–16. https://doi.org/10.1200/edbk_351336CrossRefPubMed

Uppaluri R, Campbell KM, Egloff AM et al (2020) Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated Head and neck cancer: a multicenter, phase II trial. Clin Cancer Res 26:5140–5152. https://doi.org/10.1158/1078-0432.ccr-20-1695CrossRefPubMedPubMedCentral

Wise-Draper TM, Gulati S, Palackdharry S et al (2022) Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res 28:1345–1352. https://doi.org/10.1158/1078-0432.ccr-21-3351CrossRefPubMedPubMedCentral

10.

Uppaluri R, Lee NY, Westra W et al (2019) KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma. J Clin Oncol JCO 37:TPS6090. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS6090CrossRef

11.

Zech HB, Moeckelmann N, Boettcher A et al (2020) Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. Future Oncol 16:3035–3043. https://doi.org/10.2217/fon-2020-0595CrossRefPubMed

12.

Lee NY, Ferris RL, Psyrri A et al (2021) Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 22:450–462. https://doi.org/10.1016/s1470-2045(20)30737-3CrossRefPubMed

13.

Tao Y, Biau J, Sun XS et al (2023) Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol 34:101–110. https://doi.org/10.1016/j.annonc.2022.10.006CrossRefPubMed

14.

Machiels JPTY, Burtness B et al (2022) Primary results of the phase 3 keynote-412 study: pembrolizumab plus chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma. ESMO Congress Abstract LBA5

15.

Bourhis J et al (2021) Avelumab-Cetuximab-Radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial. ESMO Virtual Congress LBA35

16.

Tosi A, Parisatto B, Menegaldo A et al ( 2022) The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors. J Exp Clin Cancer Res 41:279. https://doi.org/10.1186/s13046-022-02481-4CrossRefPubMedPubMedCentral

17.

Wang J, Sun H, Zeng Q et al (2019) HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep 9:13404. https://doi.org/10.1038/s41598-019-49771-0CrossRefPubMedPubMedCentral

18.

Succaria F, Kvistborg P, Stein JE et al (2021) Characterization of the Tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. Cancer Immunol Immunother 70:1227–1237.CrossRefPubMed

19.

Compendium, Keytruda RA (2023) https://compendium.ch/product/1346803-keytruda-inf-konz-100-mg-4ml Accessed 19 Aug 2023

20.

Food US, Administration D (2019) FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma RA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-squamous-cell-carcinoma#:~:text=squamous%20cell%20carcinoma Accessed 19 Aug 2023

21.

Food US, Administration D (2016) Pembrolizumab (KEYTRUDA) RA https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda Accessed 19 Aug 2023

22.

European Medicines Agency, Keytruda RA (2023) https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda Accessed 19 Aug 2023

23.

Food US, Administration D. Nivolumab for SCCHN (2023) https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn Accessed 2 Sept 2023

24.

European Medicines Agency, Opdivo (2023) https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo Accessed 2 Sept 2023

25.

Compendium, Opdivo (2023) https://compendium.ch/product/1379284-opdivo-inf-konz-240-mg-24ml Acessed 2 Sept 2023

26.

Park BJ, Mattox AK, Clayburgh D et al (2022) Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck. Oral Oncol 135:106183. https://doi.org/10.1016/j.oraloncology.2022.106183CrossRefPubMedPubMedCentral

27.

Karabajakian A, Bouaoud J, Michon L et al (2021) Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncol 119:105368. https://doi.org/10.1016/j.oraloncology.2021.105368CrossRefPubMed

28.

Jones D, Pereira ER, Padera TP (2018) Growth and immune evasion of lymph node metastasis. Front Oncol 8:36. https://doi.org/10.3389/fonc.2018.00036CrossRefPubMedPubMedCentral

29.

Ambrosini-Spaltro A, Limarzi F, Gaudio M, Calpona S, Meccariello G (2022) PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis. Virchows Arch 481:93–99. https://doi.org/10.1007/s00428-022-03322-7CrossRefPubMed

30.

Kaur A, Kuchta K, Watkin W et al (2023) Programmed death ligand-1 combined positive score concordance and interrater reliability in primary tumors and synchronous lymph node metastases in resected cases of p16+ oropharyngeal squamous cell carcinoma. Arch Pathol Lab Med 147:442–450. https://doi.org/10.5858/arpa.2021-0464-oaCrossRefPubMed

31.

Kalpakoff M, Hund S, Musser J et al (2021) Intrapatient tumor heterogeneity in IHC Interpretation using PD-L1 IHC 22C3 pharmDx. Appl Immunohistochem Mol Morphol 29:667–673. https://doi.org/10.1097/pai.0000000000000941CrossRefPubMedPubMedCentral

32.

De Keukeleire SJ, Vermassen T, Deron P et al (2022) Concordance, correlation, and clinical impact of standardized PD-L1 and TIL scoring in SCCHN. Cancers (Basel) 14:2431. https://doi.org/10.3390%2Fcancers14102431CrossRefPubMed

33.

Rasmussen JH, Lelkaitis G, Håkansson K et al (2019) Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer 120:1003–1006. https://doi.org/10.1038/s41416-019-0449-yCrossRefPubMedPubMedCentral

34.

Paintal AS, Brockstein BE (2020) PD-L1 CPS scoring accuracy in small biopsies and aspirate cell blocks from patients with head and neck squamous cell carcinoma. Head Neck Pathol 14:657–665. https://doi.org/10.1007/s12105-019-01097-zCrossRefPubMed

35.

Liu Z, Williams M, Stewart J, Glisson BS, Fuller C, Roy-Chowdhuri S (2022) Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Cancer Cytopathol 130:110–119. https://doi.org/10.1002/cncy.22501CrossRefPubMed

36.

Heidarian A, Wenig BM, Hernandez-Prera JC (2022) Evaluation of programmed death ligand 1 immunohistochemistry in cytology specimens of head and neck squamous cell carcinoma. Cancer Cytopathol 130(2):91. https://doi.org/10.1002/cncy.22500CrossRefPubMed

37.

Koomen BM, van der Starre-Gaal J, Vonk JM et al (2021) Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer. Cancer Cytopathol 129:304–317. https://doi.org/10.1002/cncy.22383CrossRefPubMed

38.

Fasano M, Corte CMD, Liello RD et al (2022) Immunotherapy for head and neck cancer: present and future. Crit Rev Oncol Hematol 174:103679. https://doi.org/10.1016/j.critrevonc.2022.103679CrossRefPubMed

39.

Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC (2023) Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer 23:173–188. https://doi.org/10.1038/s41568-022-00531-9CrossRefPubMed

40.

Hirsch FR, McElhinny A, Stanforth D et al (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12:208–222. https://doi.org/10.1016/j.jtho.2016.11.2228CrossRefPubMed

41.

Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13:1302–1311. https://doi.org/10.1016/j.jtho.2018.05.013CrossRefPubMedPubMedCentral

42.

Hodgson A, Slodkowska E, Jungbluth A et al (2018) PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma. Am J Surg Pathol 42:1059–1066. https://doi.org/10.1097/pas.0000000000001084CrossRefPubMedPubMedCentral

43.

de Ruiter EJ, Mulder FJ, Koomen BM et al (2021) Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol 34:1125–1132. https://doi.org/10.1038/s41379-020-0644-7CrossRefPubMed

44.

Karpathiou G, Vincent M, Dumollard JM, Mobarki M, Péoc’h M (2022) PD-L1 expression in head and neck cancer tissue specimens decreases with time. Pathol Res Pract 237:154042. https://doi.org/10.1016/j.prp.2022.154042CrossRefPubMed

Titel: Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations
verfasst von: Ruben Bill
William C. Faquin
Sara I. Pai
Publikationsdatum: 06.11.2023
Verlag: Springer US
Erschienen in: Head and Neck Pathology / Ausgabe 4/2023
Elektronische ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-023-01590-6

Springer Medizin

Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Squamous Odontogenic Tumor in the Posterior Region of Maxilla

Clinicopathological Features of Metastasis to the Oral and Maxillofacial Region—Multicenter Study

Revisiting the History of Odontoma, with Special Reference to Its Original Illustration

The First Report of Cytology of DEK::AFF2 Fusion-Associated Papillary Squamous Cell Carcinoma on Fine-Needle Aspiration

Non-Calcifying/Langerhans Cell-Rich Calcifying Epithelial Odontogenic Tumour: A Critical Review of the Rare and Distinctive Entity

Prevalence of BRAF p.V600E and Detection Methods in Benign Mixed and Malignant Odontogenic Tumors: A Systematic Review

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie